buspirone has been researched along with Breathlessness in 3 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has proven efficacy in the treatment of generalized anxiety disorder, has been suggested to relieve the sensation of dyspnea in patients with COPD." | 9.22 | Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. ( Banerjee, TK; Bushunow, PW; Dakhil, SR; Dudgeon, DJ; Flannery, MA; Garland, SN; Heckler, CE; Hopkins, JO; Kirshner, JJ; Morrow, GR; Peoples, AR; Peppone, LL; Roscoe, JA, 2016) |
| "Buspirone is an anxiolytic agent that appears to have no sedative effects." | 6.67 | Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. ( Argyropoulou, P; Georgopoulos, D; Koukou, A; Patakas, D; Vasiliadis, P, 1993) |
| " Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has proven efficacy in the treatment of generalized anxiety disorder, has been suggested to relieve the sensation of dyspnea in patients with COPD." | 5.22 | Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. ( Banerjee, TK; Bushunow, PW; Dakhil, SR; Dudgeon, DJ; Flannery, MA; Garland, SN; Heckler, CE; Hopkins, JO; Kirshner, JJ; Morrow, GR; Peoples, AR; Peppone, LL; Roscoe, JA, 2016) |
| "Buspirone is an anxiolytic agent that appears to have no sedative effects." | 2.67 | Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. ( Argyropoulou, P; Georgopoulos, D; Koukou, A; Patakas, D; Vasiliadis, P, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Currow, D | 1 |
| Johnson, M | 1 |
| White, P | 1 |
| Abernethy, A | 1 |
| Peoples, AR | 1 |
| Bushunow, PW | 1 |
| Garland, SN | 1 |
| Heckler, CE | 1 |
| Roscoe, JA | 1 |
| Peppone, LL | 1 |
| Dudgeon, DJ | 1 |
| Kirshner, JJ | 1 |
| Banerjee, TK | 1 |
| Hopkins, JO | 1 |
| Dakhil, SR | 1 |
| Flannery, MA | 1 |
| Morrow, GR | 1 |
| Argyropoulou, P | 1 |
| Patakas, D | 1 |
| Koukou, A | 1 |
| Vasiliadis, P | 1 |
| Georgopoulos, D | 1 |
2 trials available for buspirone and Breathlessness
| Article | Year |
|---|---|
Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Buspirone; Disease Management; Double-Blind Method; | 2016 |
Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Buspirone; Double-Blind Method; Dyspnea; Exercise Tolerance; Forced Expiratory Volume; | 1993 |
1 other study available for buspirone and Breathlessness
| Article | Year |
|---|---|
Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference.
Topics: Anti-Anxiety Agents; Benzodiazepines; Buspirone; Chronic Disease; Dyspnea; Evidence-Based Medicine; | 2013 |